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ABSTRACT 
 
INTRODUCTION: Diabetes mellitus type 1 (DM1) is an autoimmune disease characterized by 
metabolic destruction of pancreatic cells responsible for insulin production, with treatment based 
on replacing insulin. Long-acting insulin analogs are indicated for patients with DM1 who exhibit 
important oscillations of their daily glycemia despite their higher costs. OBJECTIVE: To evaluate 
the effectiveness and safety of two long acting insulins. insulin glargine and detemir in treating 
patients with DM1. METHODS: Systematic review with meta-analysis of observational studies 
(cohort and registry), available in the database, gray literature and complementary search in 
Diabetes Care Journal. Outcomes assessed were: glycated hemoglobin concentration, fasting 
plasma glucose or capillary, occurrence of episodes of severe hypoglycemia and occurrence of 
nocturnal hypoglycemia. The assessment of methodological quality was performed using the 
Newcastle score. The meta-analyses were performed on software Review Manager ® 5.2. 
RESULTS: Out of 705 publications, 8 cohort studies were included. The quality of these studies 
was classified as high. In the meta-analysis results regarding episodes of severe hypoglycemia 
(p = 0.02) and fasting glucose (p = 0.01) were in favour of detemir. The glycated hemoglobin (p 
= 0.49; I2= 89) showed high heterogeneity and no statistically significant difference between the 
two. The meta-analysis of total insulin dose favored glargine (p = 0.006; I2= 75). The rates of 
nocturnal hypoglycemia (NH) were evaluated only for one study and showed a significant 
reduction of NH after therapy with detemir, (p < 0.0001). CONCLUSION: Although some 
outcomes were favourable to determir insulin analogue, it has not been possible to identify 
important differences of effectiveness and safety between the two analogs. These results can 
help in the current debate on the inclusion of long-acting analogs on the list of reimbursed 
medicines in the Brazil especially with the recent introduction of insulin glargine biosimilar at 
considerably lower prices. 
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INTRODUCTION 
  
Diabetes mellitus (DM) is a heterogeneous group of metabolic disorders that includes increased 
levels of blood glucose resulting from defects in insulin action, on insulin secretion or both. DM 
is considered a chronic disease with high morbidity and mortality, being one of the leading 
causes of stroke, myocardial infarction, chronic renal failure, blindness and non-traumatic 
amputations(1, 2). Among the types of DM, DM type 1 (DM1) and DM type 2 (DM2) are the most 
prevalent DM2(3). 
 
According to the International Diabetes Federation (IDF), the number of people with DM in the 
world increased from 108 million in 1980 to 422 million in 2014, and it is estimated that this 
number will increase to 642 million by 2040. Approximately 80% of patients with DM live in 
developing countries due to the growth in populations in these countries, population aging, 
greater urbanization, the prevalence of obesity and progressive sedentariness, as well as 
increased survival of patients with DM(4). 
 
Among the therapeutic alternatives available on the market for the treatment of DM1, Neutral 
Protamine Hagedorn (NPH), which has a profile of intermediate action, is currently considered 
as standard treatment and the long acting insulin analogs, such as insulin glargine (GLA) and 
insulin detemir (DET), can be combined with fast-acting insulin for better modulation of 
pharmacotherapy and glycemic control. GLA and DET allow a more stable profile compared 
with NPH insulin, without a pronounced peak action that do not require homogenization, leading 
to possibly more flexible administration(5, 6). 
 
However, a number of meta analyses and other studies conducted to date do not support the 
clinical superiority of GLA and DET compared to NPH. In four systematic reviews(6-9), there 
appeared to be no additional clinical benefit of GLA compared with NPH insulin in terms of both 
effectiveness and side-effects. Similar results were seen observed in a recent cohort study(10) as 
well as in a recent systematic review comparing the quality of life or patient-reported outcomes 
between GLA versus NPH insulin(11).  Despite these and similar studies of long-action insulins 
versus NPH insulin(6-10,12-13), with concerns echoed by the Brazilian Agency of Health 
Technology Assessment (Comissão Nacional de Incorporação de Tecnologias no SUS - 
CONITEC)(14) resulting in long-acting insulins  not being recommended for inclusion in the list of 
official reimbursed medicines, GLA has been incorporated into the list of the State Secretary of 
Health of the State (Secretaria Estadual de Saúde do Estado de Minas Gerais SES/MG) in 
Brazil. This resulted in public spending of approximately US $6 million in 2011 for long acting 
insulins since the difference between the cost of monthly treatment Brazil was 536% for GLA 
versus NPH, 377% for DET vs. NPH and 34% for GLA vs. DET(7, 14). 
  
Concerns with the additional costs of long-action insulin analogs has resulted in some countries 
restricting the indications for funding(6). In Brazil, SES / MG attempted to restrict the free supply 
of GLA to patients with DM1 who demonstrate inadequate glycemic control and/or episodes of 
frequent hypoglycemia following NPH insulin; however, there are still requests from patients 
with DM2 and/or those patients outside the established criteria(15). Whilst Siebenhofer-Kroitzsch 
et al. also question the clinical relevance of potential minor improvements with insulin analogs 
versus NPH insulins, they may have a place in selected patients such as those with higher 
occurrence of nocturnal hypoglycemia(16). It is also worth noting that investment in self-
management programs for patients with DM have resulted in sustained clinical gain in terms of 
glycemic control and a reduced risk of severe hypoglycemia than has been observed with long-
action insulins(14). Never-the-less, long-acting insulin analogues are available in Brazil with 
restrictions on their use in SES / MG.  
  
In view of concerns with cost differentials between different long-acting insulins in some 
countries, improved kidney function in some patients with the long-acting analogues, although 
still concerns with their overall benefit versus NPH insulins, and potential differences in 
effectiveness between the long-acting insulins with differences in action between them (6- 8,17-19), 
the objective of this study is to evaluate the effectiveness and safety of GLA in comparison to 
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DET in patients with DM1 through a systematic review and meta- analysis. The results will help 
inform future decision making in Minas Gerais as well as wider in Brazil and other countries 
especially as more biosimilars of long-acting insulins become available. 
 
MATERIAL AND METHOD 
  
This review was conducted in accordance with guidelines of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA)(20) with registration protocol, CRD number 
42017054925 in the International Prospective Register of Ongoing Systematic Reviews  
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017054925). 
  
Databases and search strategy 
  
An electronic search was performed in articles published until August to 2017 in databases 
including MEDLINE (Pubmed), Latin American literature and Caribbean Health Sciences 
(LILACS), EMBASE and Cochrane Library. Various combinations of terms were used following 
the peak (population, intervention strategy, comparing, and result): DM1, GLA and DET (Table 
1). As a complement to the electronic search, a search was carried out on the references of all 
included studies as well as in the electronic journal Diabetes Care from 2003 to August 2017. 
We also made a search of grey literature studies included in the bank of theses and 
dissertations of the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) 
and Digital Library of Theses and Dissertations at the Federal University of Minas Gerais 
(UFMG) in case we had missed any important studies. 
  
Table 1 - Search Strategies 
  
Electronic 
Bases 
Search strategies Files 
Retrieved 
MEDLINE 
(PUBMED)  
 (((((((((((((((((((((((((("Diabetes Mellitus, Type 1" [Mesh]) 
OR "Diabetic Ketoacidosis" [Mesh]) OR Insulin-
Dependent Diabetes Mellitus [Text Word]) OR Diabetes 
Mellitus, Insulin-Dependent, 1 [Text Word]) OR Diabetes 
Mellitus Juvenile-Onset [Text Word]) OR Juvenile-Onset 
Diabetes Mellitus [Text Word]) OR Diabetes Mellitus, 
Sudden Onset [Text Word])) OR IDDM [Text Word])) OR 
Juvenile-Onset Diabetes [Text Word])) OR Diabetes 
Mellitus Brittle [Text Word])) OR Diabetes Mellitus 
Ketosis-Prone [Text Word])) OR Diabetes, Autoimmune 
[Text Word])) Or Autoimmune Diabetes [Text Word])) OR 
Ketoacidoses, Diabetic [Text Word])) OR Acidosis, 
Diabetic [Text Word])) AND ((((((((((((, Insulin Detemir 
[MeSH Terms]) OR Basal Insulin Detemir [Text Word])) 
OR Detemir Basal Insulin, [Text Word])) OR Insulin 
Detemir, Basal [Text Word]) ) OR NN304 [Text Word])) 
OR NN-304 [Text Word])) OR Levemir [Text Word])) AND 
((((((((Glargine, Insulin [MeSH Terms]) OR Glargine [Text 
Word])) OR HOE 901 [Text Word])) OR 901, HOE [Text 
Word])) OR Lantus [Text Word])) 
117 
EMBASE 
  
#1 ' diabetic ketoacidosis '/exp OR ', diabetic acidosis ' 
OR ' diabetes ' OR ' acidosis ketoacidosis diabetes ' OR ' 
diabetes ' OR ' ketosis ' OR ' diabetic acidosis diabetic 
ketosis ' OR ' insulin dependent diabetes mellitus '/exp 
OR ' brittle ' OR ' brittle diabetes diabetes mellitus ' OR ' 
diabetes mellitus type 1 ' OR ' type i diabetes mellitus ' 
OR ' diabetes mellitus, insulin-dependent diabetes 
mellitus, ' OR ' type 1 ' OR ' diabetes, type i diabetes 
mellitus, ' OR ' brittle ' OR ' diabetes, insulin dependent 
diabetes mellitus ' OR ' juvenile onset ' OR ' diabetes type 
1 diabetes type ' OR ' i ' OR ' diabetes, juvenile ' OR ' dm 
' OR 1 ' early onset diabetes mellitus ' OR ' iddm insulin 
472 
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dependent diabetes ' OR ' ' OR ' juvenile diabetes ' OR ' 
juvenile diabetes mellitus ' OR ' juvenile onset diabetes ' 
OR ' juvenile onset diabetes mellitus ' OR ' ketoacidotic 
diabetes ' OR ' labile diabetes mellitus ' OR ' type 1 ' OR ' 
type 1 diabetes diabetes mellitus ' OR ' type i diabetes ' 
OR ' type i diabetes mellitus ' #2 '/exp ' OR ' insulin 
isophane nph insulin glargine ' #3 '/exp ' OR ' abasaglar ' 
OR ' abasria ' OR ' basaglar ' OR ' insulin glargine ' Or ' 
hoe 901 ' OR ' hoe901 ' OR ' insulin glargine recombinant 
' OR ' insulin [a21 glycine b31 b32 arginine arginine] ' OR 
' lantus ' OR ' lantussolostar ' OR ' ly ' OR ' 2963016 ' OR 
' ly2963016 ' OR ' optisulin optisulin depot ' OR ' optisulin 
long ' OR ' toujeo ' #3 '/exp ' OR ' detemir insulin levemir ' 
And cohort analysis '/exp ' OR ' controlled clinical trial 
'/exp OR '/exp #1 ' AND #2 epidemiology AND #3 AND #4 
COCHRANE  
LIBRARY 
#1 MeSH descriptor: [Diabetes Mellitus, Type 1] explodes 
all trees #2 MeSH descriptor: [Diabetic Ketoacidosis] 
explodes all trees #3 Diabetes Mellitus, Insulin-
Dependent (Word variations have been searched), 
Insulin Dependent Diabetes Mellitus #4 (Word variations 
have been searched) #5 Diabetes Mellitus, Insulin 
Dependent Juvenile Onset $ #6-#7 Diabetes Mellitus 
Type 1 Diabetes #8 Diabetes Mellitus, Type I Diabetes, 
Autoimmune #9 #10 {or #1-#9} #11 MeSH descriptor: 
[Insulin Glargine] explodes all trees glargine Lantus #13 
#12 #14 {#11-#13 or } #15 MeSH descriptor: [Insulin 
Detemir] explodes all trees #16, Insulin Detemir (Word 
variations have been searched)  
Insulin Detemir Basal #17 (Word variations have been 
searched) #18 Basal Insulin Detemir,: ti, ab, kw (Word 
variations have been searched) Levemir #19 #20 {or #15-
#19} #21 #14 #20 #22 #10 and #21 and #23 MeSH 
descriptor: [Cohort Studies] explodes all trees $ cohort 
epidemiologic methods #25 #24 #26 controlled clinical 
trial #27 {or #23 -#26} #28 #22 and #27  
109 
LILACS (((((((("DIABETIC KETOACIDOSIS") or "DIABETES 
MELLITUS TYPE 1") or "INSULIN-DEPENDENT" 
DIABETES MELLITUS) or "AUTOIMMUNE DIABETES") 
or "DIABETES MELLITUS") or "KETOACIDOSIS 
DIABETICA") or "DIABETES") or "IDDM") or "INSULIN-
DEPENDENT DIABETES MELLITUS" [Words] an d 
((("GLARGINE") or "LANTUS") or "LANTUS 
SOLOSTAR") or "GLARGINE" [Words] and 
(("DETEMIR") or "LEVEMIR") or "INSULIN DETEMIR" 
[Words] 
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Selection of studies and eligibility criteria 
  
Cohort studies were selected as well as database records of concurrent and non-concurrent 
patients with DM1. Considered studies included those that assessed GLA vs. DET principally in 
terms of their effectiveness and safety. 
  
We excluded studies that concentrated on dose comparisons, compared other drugs apart from 
GLA and DET, pregnant patients, clinical protocols, reviews, case reports, studies in animals, in 
vitro studies, pharmacodynamic studies and/or studies that combined oral antidiabetic 
medicines with insulin therapy for DM1, as well as studies that included less than 30 
participants or follow-up time was less than four weeks, similar to Marra et al.(7) 
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Data collection and methodological quality assessment 
  
The studies found in the electronic databases were allocated on a single basis to exclude 
duplicates using the EndNote software programme. Two independent reviewers (TS and PA) 
evaluated the titles (Phase 1), the abstracts (Phase 2) and the full text (Phase 3). 
Disagreements were resolved by a third reviewer (VA). The data, including methodological 
quality, participant information, treatment duration, effectiveness and safety data, were 
extracted and collected independently with each reviewer on a previously formulated and tested 
Excel spreadsheet for this purpose.  
 
For the assessment of methodological quality, we used the Newcastle-Ottawa scale(21). This 
scale was originally developed to evaluate the quality of observational studies. On this scale, 
each study is evaluated in three dimensions. These include the selection of the study groups, 
comparability of groups and the calculation of exposure or outcome of interest. The total score 
of nine is considered to be of high quality. In addition, funding sources have been identified and 
explored in view of concerns with bias identified in the previous systematic review of Marra et 
al.(7)and Almeida et al.( 11). The possibility of publication bias was assessed via analysis using a 
funnel plot.(22) It was considered that there was no conflict of interest in any part of the text if no 
comment about conflict of interest was found. Conflict of interest refers to sources of funding 
from pharmaceutical companies or when there was a bond with any of the authors of the study 
with the pharmaceutical companies. This could include speaker fees or funding for conferences.  
  
Summary of the findings and statistical analysis 
  
The outcomes assessed were the glycated hemoglobin concentration (HbA1c), fasting plasma 
glucose or capillary and occurrence of episodes of severe hypoglycemia and occurrence of 
nocturnal hypoglycemia.  
  
The data from the studies were combined using the random effects model of Review Manager 
software version 5.3. The results were presented by the mean difference (MD) for continuous 
variables with a 95% confidence interval (IC95%). Analyses with a heterogeneity (I2) greater 
than 40%, and a p-value chi-square test less than 0.10, were considered as high/significant 
heterogeneity. Sensitivity analysis was conducted to investigate the causes of the 
heterogeneity, excluding a study at a time and observed changes in I2 values and p-value.(22) 
  
RESULTS 
  
Included studies 
 
705 publications were found in electronic databases. After deleting duplicates, 609 articles were 
selected for analysis of the titles and abstracts and 13 for complete reading. After the analysis 
of the articles using our inclusion criteria, only seven studies were finally selected and the 
manual search added another publication, totaling eight studies for inclusion in the meta-
analysis (Figure 1). Overall, a total of 596 studies were excluded in the first phase after reading 
titles and abstracts (Figure 1). Following this, as mentioned, 13 studies were progressed to full 
reading. One study was excluded (Tsujino et al.)(23) as the authors had a sample of less than 30 
participants. Two studies (Kurtoglu et al. and Philips et al.)(24,25) were excluded due to the lack of 
information and a detailed design of the study, and three studies (Derosa et al., 3ODYãLüet al., 
and Hopkinson et al.)(26-28) were excluded due to differences in the type of intervention. 
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Figure 1- Study selection chart 
 
 
 
Characteristics of included studies 
  
Of the eight cohort studies retrieved, three were non-concurrent design(29-31) and five, concurrent 
(32-36). Five studies were multicenter studies (30,32,33,35,36) and three were single centre 
studies(29,31,34). The follow-up time ranged from 3.5 to 54 months (Table 2).  
  
Five studies(30, 33, 34-36) declared conflicts of interest, one(31) stated the absence of conflicts of 
interest and two(39, 32) didn't mention this. Only two studies(39, 32) did not report funding, five 
studies(30, 33-36) were funded by the pharmaceutical industry and a single study(31) had its own 
financing. Two studies evaluated only pediatric patients, five studies only adult patients and one 
study both adults and children. The eight studies included a total of 9,375 patients (Table 2).  
  
With respect to the characteristics of patients, the average age ranged between 12 and 49 
years, 56% were men, and the average disease duration ranged from 4 and 21 years. 
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Table 2 ± General characteristics of included studies  
 
Methodological quality 
  
No studies obtained the maximum score of nine stars on the Newcastle-Ottawa scale (Table 2). 
Four studies scored seven, three six, and one scored five. The quality of the included studies 
was ranked as high. There was asymmetry in the funnel plot (Figure 2) for the HbA1c outcome, 
suggesting an influence of publication bias. 
 
Figure 2 ± Funnel plot of MD in HbA1c. MD mean difference, SE standard error 
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Summary of the findings 
  
To assess the effectiveness and safety of the different long-acting insulins in meta-analysis, the 
following outcomes were included: HbA1c, sever hypoglycaemia, total dose of insulin and 
fasting glucose. As for the outcome of events of NH, we described only the results presented in 
each study since they did not provide data in pairs that could be combined in a meta-analysis. 
 
Table 3 - Result of meta-analysis  
 
 
 
 
HbA1c analysis were included six studies(29, 31, 33-36). The results did not favor any of the two long 
acting insulins (p = 0.49), with an average difference of 0.10 (CI:-0.17, 0.37, p < 0.00001; I2= 
89%), and significant heterogeneity (Figure 3). 
 
Figure 3 - Meta-analysis Glycated Hemoglobin (%) 
 
In the meta-analysis that assessed the total dose of insulin administered, four studies were 
included(29, 31, 34, 35). There was a statistically significant difference favoring GLA (p = 0.006) in -
0.07 (CI:-0.12, 0.02, p = 0.007; I2= 75%) and with a significant heterogeneity (Figure 4). 
 
Figure 4 ±  Meta-analysis full dose of insulin (U/kg/day) 
 
 
 
In the meta-analysis that assessed the occurrence of severe hypoglycemia, only two studies were 
included(30,36). The data showed a statically significant difference favoring DET (p = 0.002), with a 
difference of average 0.68 (CI: 0.26, 1.10, p = 0.30; I2= 8%) (Figure 5). 
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Figure 5 ± Meta-analysis severe hypoglycemia (episodes/person-year) 
 
 
Five studies were included when evaluating fasting glucose levels(32-36). The result was statistically 
significant favoring DET (p = 0.01), with an average difference of 0.64 (CI: 0.13, 1.15, p < 0.00001; 
I2= 89%) with a high heterogeneity (Figure 6). 
 
Figure 6 - Meta-analysis fasting glucose (mmol/L) 
 
Nocturnal hypoglycemia events were assessed in the meta-analysis because the studies did not 
present data that could be combined. In the study of Yenigun et al(35) nocturnal hypoglycemia 
events per patient-year were reduced to 10.01 with GLA once a day and to 3.77 with DET once 
a day (p < 0.0001). Dornhost et al(36) noted a decrease of 10.1 nocturnal hypoglycemia events per 
patient-year with GLA vs. DET (p < 0.0001). 
In the study of Haukka et al(30), DET presented a lower risk of 13.1% (1.0%), 29.6% -23.6 (-47.8%) 
and 17.9 5.1% (3.6-30.1%) for the occurrence of the first recurring hypoglycemia as well as 
hypoglycemia and coma hypoglycemic (p = 0034, p = 0.021, p = 0.016), respectively, versus GLA. 
  
Analysis of Subgroups 
  
The outcome of HbA1c was also evaluated in two subgroups: the time of follow-up and the 
presence of conflict of interest. 
  
Studies classified as intermediate follow-up(31,33,34) (Table 2) had not statistically significant 
findings (p = 0.51) (MD =-0.19; IC:-0.74, 0.37, p < 0.0001; I2 = 93%). In longer duration studies(29, 
35), the difference of the average was estimated at 0.43 (IC: 0.22, 0.64, p = 0.36; I2= 0%) favouring 
DET. When consolidated, an estimate of the difference of the average was 0.10 (CI:-0.17, 0.37, 
p < 0.00001; I2= 89%) with high heterogeneity and did not favor either of the two long acting 
insulin. Sensitivity analyses excluding one study(31) affected the outcome favoring DET (p = 
0.0005) and decreasing the heterogeneity for I2= 61% (Table 3, Figure 7). 
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Figure 7 - Meta-analysis Glycated Hemoglobin (%)-subgroup of the study duration 
 
In the subgroup without studies of conflicts of interest(29, 31), there were no statistically significant 
differences in HbA1c (DM = -0.45, CI = -1.43, 0.52, p = 0.02, I2 = 82%). In the subgroup with 
studies of conflicts of interest (33-36), there was an estimated average difference of 0.30 (CI: 0.14, 
0.46, p = 0.01, I2 = 72%) favoring DET. The total results showed no statistically significant 
difference between the two long-acting insulins with a mean difference of 0.10 (CI: -0.17, 0.37, p 
< 0.00001, I2 = 89%) with high heterogeneity (Table 3, Figure 8). The exclusion of any studies in 
the sensitivity analyzes affected the direction of the result. 
 
Figure 8 - Meta-analysis Glycated Hemoglobin (%) - conflict of interest subgroup 
 
 
DISCUSSION 
  
Faced with a chronic disease such as DM1, which requires that patients take care of 
themselves over a long period of time, it is necessary to outline a plan of action which can be 
modified when new clinical findings and/or laboratory results justify such modification. Intensive 
therapy, bringing together multiple daily injections and self-monitoring, aiming to achieve 
improved glycemic control, are considered the optimal treatment for the DM1 to reduce of the 
risk of complications. Strict control of DM1 can delay the progression of chronic microvascular 
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complications in approximately 50% of cases, which makes the treatment of DM1 cost-effective 
(37).  
 
The availability of long-acting insulins adds to the armamentarium where there are concerns 
with control of HbA1c and hypoglycaemia with current approaches. The findings from our meta-
analysis of Hb1Ac found no differences between the two long-acting insulins (GLA and DET) in 
terms of glycemic control. Similar results were also described in randomized clinical trials 
(RCTs) and systematic reviews that compared GLA, DET and NPH insulin (9-12, 33,34,38). Swinnen 
et al in their earlier systematic review of RCTs comparing GLA vs. DET also showed that 
glycemic control, as measured by the Hb1Ac, did not differ statistically significant between the 
different long-acting insulins(39), adding to our findings. 
 
When evaluating the results of HbA1c, the subgroup of studies free of conflict of interest did not 
show statistically significant difference between GLA vs. DET. In the subgroup with conflicts of 
interest, the results favoured DET, but the reference values for HbA1c control, recommended by 
the American Diabetes Association as below 7.0%, were not achieved(37). Bekelman et al claim 
that financial relations between the industry, researchers and academic institutions, can lead to 
favorable results for the sponsor, which can compromise patient's subsequent welfare(40). 
Similar results were found in a previous meta-analysis(10). 
 
Two studies were included in the meta-analysis of doses used, with the results favorable to 
GLA. A daily dose (possibly two) is a basal scheme, with lispro/asparte/glulisine before each 
meal or, in the case of unpredictability of food intake (common in children), immediately after 
the meal. Despite GLA and DET having very similar absorption curves, there are differences 
between the two insulins, as a side-chain fatty acid promotes the formation of hexamers in the 
injection site, decreasing the absorption of DET and prolonging even further its action, indicating 
that the doses of DET should be about 30% higher than the doses of NPH used previously(41). 
On the other hand, there seems to be less intra-individual variation with the use of DET 
compared with GLA and NPH(42). 
 
The result of the meta-analysis of severe hypoglycemia involving 8598 patients showed 
statistically significant results favouring DET. Singh et al(8) showed that the DET reduced the 
risk of occurrence of episodes of severe hypoglycemia and nocturnal in relation to NPH, an 
advantage not seen with GLA insulin. Pieber et al.(43) showed that the use of DET is equally 
effective in glycemic control versus GLA in patients with DM1, but with less daytime 
hypoglycaemia or severe hypoglycemia. However, in relation to the control of episodes of 
hypoglycemia (any episode of hypoglycemia), the meta-analysis by Monami et al(9) showed that 
the incidence of any event of hypoglycemia was equal among the long-acting insulin analogs 
and NPH insulin. 
 
In this context, self-management is integral to the control of DM1 as it allows patients to assess 
their individual response to therapy with insulin as well as monitor whether blood glucose 
targets are being effectively achieved, and may be useful in preventing hypoglycemia or 
hyperglycemia symptoms and therapeutic adjustment(44).  
 
The results of the meta-analysis of fasting glucose also favored DET, with lower values in 
patients treated with DET when compared to the GLA. However, recent studies have 
questioned this parameter to monitor the glycemic control of patients, because it reflects a one-
time non-recurring measure, at the time of blood collection(37). 
 
Although some results favored the DET, in most cases, the therapeutic goal for glycemic control 
was not achieved in the groups of patients monitored. This can be due to barriers which the 
disease imposes, such as the occurrence and the fear of hypoglycemic events, the complexity 
of daily treatment, the need for self-monitoring and frequent adjustments of insulin doses and 
because in routine clinical care the results from long-acting insulin analogs may not duplicate 
those observed in RCTs(4-8). Consequently, the choice of long-acting insulin analogs should be 
based in the individual characteristics of the patient, the effectiveness of existing therapies and 
any cost differential between the different insulins. 
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Currently, the annual costs of treating people with DM represents approximately 12% of total 
health expenditure in the world(4). Whilst not the subject of this review, the cost differential 
between GLA, DET and NPH insulins must be considered especially in healthcare systems 
striving for, or currently attaining, universal access within finite resources. A study conducted by 
the Canadian Agency for Drugs and Technologies in Health (CADTH) compared the cost-
effectiveness of GLA and DET with NPH in patients with DM1 and DM2, and noted that the 
long-action analogs are not cost effective and that the substitution of NPH by DET and GLA in 
patients with DM1 would be costly to the Canadian health system(13). Evaluations carried out in 
the United Kingdom estimated savings of up to US $836 million over a decade with greater use 
of NPH versus long-action analogs(45). The savings would have been higher if you take into 
account the Brazilian perspective, since in the United Kingdom the cost differential between 
long-action analogs and NPH insulin is lower than the 536% differential that currently exists in 
Brazil.  
 
However in 2017, the National Agency of Sanitary Vigilance (Agência Nacional de Vigilância 
Sanitaria - ANVISA) of Brazil registered GLA biosimilar (Abasagar), with its price determined by 
the Regulation of the Marketing of Medicines (Câmara de Regulação do Mercado de 
Medicamentos - CMED) at 70% lower than originator GLA and 45% lower than DET(46,47). This 
systematic review and meta analysis, along with other studies and economic analyses, can help 
health authorities, and those responsible for the coordination of health programs and services 
within finite resources in Brazil and other countries with universal healthcare, re-evaluate the 
possible incorporation of different long-action analogs into the list of publicly funded of 
medicines, as well as potentially help with price negotiations. In Germany after the authorities 
recommended the exclusion of short acting insulin analogs since there were no data 
demonstrating superiority over NPH insulin to justify significantly higher prices, the 
manufacturers introduced significant price to keep them reimbursed(48). A similar approach could 
be adopted in Brazil, as well as in the State of Minas Gerais, as more biosimilar long-acting 
analogues become available with limited differences between them in terms of their clinical 
effectiveness and safety, and potentially considerable price reductions versus the originators. 
These are considerations for the future. 
 
We acknowledge there are limitations of this systematic review. It included cohort studies with 
the intrinsic selection bias of observational studies. There were also differences in the number 
of participants between the groups and the monitoring period between studies. Nevertheless 
observational studies generally have greater statistical power and a population closer to the 
"real world", i.e. with broader inclusion criteria, without exclusion of patients potentially more 
serious and without the strict limits of RCTs.  
 
The selected data to the meta-analysis can also be influenced by publication bias, that is, the 
tendency of the published results is systematically different from reality. An analysis of clinical 
trials registered on the basis of Protocol ClinicalTrial.gov revealed that less than 70% of studies 
are published(49). The non-publication of results may be due to the decision of the author or the 
funder of the study where there are unfavourable findings; alternatively, less interest from 
publishers of scientific journals where there are negative results or results without statistical 
significance. The publication bias, with the selection of favorable results, can also influence the 
data used in meta-analyses(40). To minimize the potential for publication bias, a comprehensive 
search was conducted including gray literature and complementary searches. However, in this 
systematic review analysis of the funnel plot we found asymmetry. Most of the studies though 
showed great precision, usually performed with large samples, and distributed symmetrically in 
the upper part of the funnel. Only the study by Kabadi et al.(31) showed lower precision, located 
on the outside of the funnel.  Another limitation of our meta analysis was the small number of 
studies included in the review and the lack of complete and accurate information for inclusion in 
the quantitative analyses as few published studies made direct comparison between GLA vs. 
DET, which hindered the explanation of the sources of heterogeneity. In relation to the 
sensitivity analysis, the inclusion and exclusion of studies in each comparison did not changed 
the direction of the most outcome measures, without significant changes in heterogeneity, with 
exception of Kabadi et al.(31)  which when deleted the analysis changed the direction of the 
results that favor the DET. Overall, the scarcity of studies comparing GLA vs. DET, and the 
absence of other analysis with ³real-world´ data, make it difficult to fully compare the results. 
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Never-the-less, we believe our findings are robust providing direction to the authorities in Brazil 
and wider. 
  
CONCLUSION 
  
Although some results are favourable to DET, it has not been possible to identify differences in 
effectiveness and safety compared to the GLA. This would require new long-term studies and 
better methodologies. Never-the-less, our findings suggesting limited clinical differences 
between the different long-acting insulin analogs can help in the current debate on the inclusion 
of long-acting analogs, including biosimilars, in the official list of medicines reimbursed in the 
Brazil. The market entry of GLA and other future biosimilars can assist with price negotiations 
and subsequent listing including potentially expanding population groups. It is important to note 
though that for a good glycemic control, therapeutic interventions should be accompanied by 
continuous monitoring of blood glucose, dietary interventions and effective education. These are 
considerations for the future. 
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